Revlon
This article was originally published in The Rose Sheet
Executive Summary
U.S. market share of the Revlon and Almay brands combined declined 5.3% to 21.3% in the third quarter. Revlon share did not decline by 5.3% and Almay share did not drop by 21.3% as reported in the Nov. 22 issue of "The Rose Sheet" (1"The Rose Sheet" Nov. 22, 2004, p. 4)...
You may also be interested in...
Revlon Initiates Ad Campaign Review
Revlon will undertake a review of its existing ad campaign, indicating the company may be looking to reposition its marketing approach as it continues to struggle to jumpstart sales
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.